The company has a 1 Year high price target of $3. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS , which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus , rheumatoid arthritis, multiple sclerosis, Sjogren’s Syndrome, Graves’ Disease and others.